Hepatitis B Virus Infection in Human Immunodeficiency Virus Infected Southern African Adults: Occult or Overt - That Is the Question

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Bell, Trevor G ^a   Makondo, Euphodia ^a   Martinson, Neil A ^a,b   Kramvis, Anna ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; PRIMER DNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; POLYMERASE CHAIN REACTION; SEXUAL TRANSMISSION; SOUTH AFRICA; SUPERINFECTION; VIRUS GENOME; VIRUS LOAD; BLOOD; DISEASE TRANSMISSION; GENETICS; HEPATITIS B VIRUS; LIVER CIRRHOSIS; METABOLISM; NONPARAMETRIC TEST; PATHOLOGY; PREVALENCE; REAL TIME POLYMERASE CHAIN REACTION; RURAL POPULATION; SEROLOGY;

HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

ADULT; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; PREVALENCE; REAL-TIME POLYMERASE CHAIN REACTION; RURAL POPULATION; SEROLOGIC TESTS; SOUTH AFRICA; STATISTICS, NONPARAMETRIC;

EID: 84867029138     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045750     Document Type: Article

References (50)

1. UNAIDS (2010) UNAIDS report on the global AIDS epidemic 2010. Available: http://www.unaids.org/en/dataanalysis/. Accessed 2011 November 16.
2. Kramvis A, Kew MC, (2007) Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associations of genotypes. Hepatol Res 37: S9-S19.
3. Burnett RJ, Francois G, Kew MC, Leroux-Roels G, Meheus A, et al. (2005) Hepatitis B virus and human immunodeficiency virus co-infection in sub-Saharan Africa: a call for further investigation. Liver Int 25: 201-213.
4. Chung RT, (2006) Hepatitis C and B viruses: the new opportunists in HIV infection. Top HIV Med 14: 78-83.
5. Thio CL, Seaberg EC, Skolasky R, Phair J, Visscher B, et al. (2002) HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360: 1921-1926.
6. Chun HM, Roediger MP, Hullsiek KH, Thio CL, Agan BK, et al. (2011) Hepatitis B Virus Coinfection Negatively Impacts HIV Outcomes in HIV Seroconverters. J Infect Dis 205: 185-193.
7. Thomas DL, (2006) Growing importance of liver disease in HIV-infected persons. Hepatology 43: S221-229.
8. Soriano V, Sheldon J, Ramos B, Nunez M, (2006) Confronting chronic hepatitis B virus infection in HIV: new diagnostic tools and more weapons. Aids 20: 451-453.
9. Boyles TH, Cohen K, (2011) The prevalence of hepatitis B infection in a rural South African HIV clinic. S Afr Med J 101: 470-471.
10. Firnhaber C, Reyneke A, Schulze D, Malope B, Maskew M, et al. (2008) The prevalence of hepatitis B co-infection in a South African urban government HIV clinic. S Afr Med J 98: 541-544.
11. Firnhaber C, Viana R, Reyneke A, Schultze D, Malope B, et al. (2009) Occult hepatitis B virus infection in patients with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg, South Africa. Int J Infect Dis 13: 488-492.
12. Mphahlele MJ, Lukhwareni A, Burnett RJ, Moropeng LM, Ngobeni JM, (2006) High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J Clin Virol 35: 14-20.
13. Lukhwareni A, Burnett RJ, Selabe SG, Mzileni MO, Mphahlele MJ, (2009) Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a Tertiary Hospital. J Med Virol 81: 406-412.
14. Matthews GV, Manzini P, Hu Z, Khabo P, Maja P, et al. (2011) Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa. AIDS 25: 1727-1735.
15. Hoffmann CJ, Charalambous S, Martin DJ, Innes C, Churchyard GJ, et al. (2008) Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 47: 1479-1485.
16. Burnett RJ, Ngobeni JM, Francois G, Hoosen AA, Leroux-Roels G, et al. (2007) Increased exposure to hepatitis B virus infection in HIV-positive South African antenatal women. Int J STD AIDS 18: 152-156.
17. Barth RE, Huijgen Q, Tempelman HA, Mudrikova T, Wensing AM, et al. (2011) Presence of occult HBV, but near absence of active HBV and HCV infections in people infected with HIV in rural South Africa. J Med Virol 83: 929-934.
18. Mayaphi SH, Roussow TM, Masemola DP, Olorunju SA, Mphahlele MJ, et al. (2012) HBV/HIV co-infection: the dynamics of HBV in South African patients with AIDS. S Afr Med J 102: 157-162.
19. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, et al. (2008) Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 49: 652-657.
20. Shisana O, Rehle T., Simyabi L. C., Zuma K., Jooste S., Pillay-van-Wyk V., Mbelle N., Van Zyl J Parker W., Zungu N. P., Pezi S. and the SABSSM III Implementation Team (2009) South African national HIV prevalence, incidence, behavior and communication survey 2008: A turning tide among teenagers? Cape Town: HSRC Press.
21. National Department of Health SA (2004) National Antiretroviral Treatment Guidelines: Jacana, Minuteman Press.
22. Leers MP, Kolgen W, Bjorklund V, Bergman T, Tribbick G, et al. (1999) Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 187: 567-572.
23. Lebensztejn DM, Skiba E, Sobaniec-Lotowska M, Kaczmarski M, (2005) A simple noninvasive index (APRI) predicts advanced liver fibrosis in children with chronic hepatitis B. Hepatology 41: 1434-1435.
24. Lo Re V 3rd, Frank I, Gross R, Dockter J, Linnen JM, et al. (2007) Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr 44: 315-320.
25. Kwok S, Higuchi R, (1989) Avoiding false positives with PCR. Nature 339: 237-238.
26. Weinberger KM, Wiedenmann E, Bohm S, Jilg W, (2000) Sensitive and accurate quantitation of hepatitis B virus DNA using a kinetic fluorescence detection system (TaqMan PCR). J Virol Methods 85: 75-82.
27. Firnhaber C, Chen CY, Evans D, Maskew M, Schulz D, et al. (2012) Prevalence of hepatitis B virus (HBV) co-infection in HBV serologically-negative South African HIV patients and retrospective evaluation of the clinical course of mono- and co-infection. Int J Infect Dis 16: e268-272.
28. R Development Core Team (2011) R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing. Available: http://www.R-project.org. Accessed 2010 June.
29. Kew MC, (1996) Progress towards the comprehensive control of hepatitis B in Africa: a view from South Africa. Gut 38 Suppl 2: S31-36.
30. Vardas E, Mathai M, Blaauw D, McAnerney J, Coppin A, et al. (1999) Preimmunization epidemiology of hepatitis B virus infection in South African children. J Med Virol 58: 111-115.
31. Grinsztejn B, Smeaton L, Barnett R, Klingman K, Hakim J, et al. (2011) Sex-associated differences in pre-antiretroviral therapy plasma HIV-1 RNA in diverse areas of the world vary by CD4(+) T-cell count. Antivir Ther 16: 1057-1062.
32. Togashi H, Hashimoto C, Yokozawa J, Suzuki A, Sugahara K, et al. (2008) What can be revealed by extending the sensitivity of HBsAg detection to below the present limit? J Hepatol 49: 17-24.
33. Avettand-Fenoel V, Thabut D, Katlama C, Poynard T, Thibault V, (2006) Immune suppression as the etiology of failure to detect anti-HBc antibodies in patients with chronic hepatitis B virus infection. J Clin Microbiol 44: 2250-2253.
34. Sun HY, Lee HC, Liu CE, Yang CL, Su SC, et al. (2009) Factors associated with isolated anti-hepatitis B core antibody in HIV-positive patients: impact of compromised immunity. J Viral Hepat 17: 578-587.
35. Hollinger FB, (2008) Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion 48: 1001-1026.
36. Chu CM, Liaw YF, (2012) Prevalence of and Risk Factors for Hepatitis B Viremia After Spontaneous Hepatitis B Surface Antigen Seroclearance in Hepatitis B Carriers. Clin Infect Dis 54: 88-90.
37. Cohen Stuart JW, Velema M, Schuurman R, Boucher CA, Hoepelman AI, (2009) Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J Med Virol 81: 441-445.
38. Lo Re V 3rd, Kostman JR, Gross R, Reddy KR, Mounzer K, et al. (2007) Incidence and risk factors for weight loss during dual HIV/hepatitis C virus therapy. J Acquir Immune Defic Syndr 44: 344-350.
39. Shire NJ, Rouster SD, Rajicic N, Sherman KE, (2004) Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr 36: 869-875.
40. Gerlich WH, Bremer C, Saniewski M, Schuttler CG, Wend UC, et al. (2010) Occult hepatitis B virus infection: detection and significance. Dig Dis 28: 116-125.
41. Vento S, di Perri G, Luzzati R, Cruciani M, Garofano T, et al. (1989) Clinical reactivation of hepatitis B in anti-HBs-positive patients with AIDS. Lancet 1: 332-333.
42. Thio CL, (2009) Hepatitis B and human immunodeficiency virus coinfection. Hepatology 49: S138-145.
43. Gilson RJ, Hawkins AE, Beecham MR, Ross E, Waite J, et al. (1997) Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS 11: 597-606.
44. Tanaka Y, Hasegawa I, Kato T, Orito E, Hirashima N, et al. (2004) A case-control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D. Hepatology 40: 747-755.
45. Makondo E, Bell TG, Kramvis A, (2012) Genotyping and molecular characterization of hepatitis B virus (HBV) from antiretroviral treatment naive human immunodeficiency virus (HIV)-infected southern African adults. PlosOne (in press) pp. e46345 doi:10.1371/journal.pone.0046345.
46. Melegari M, Bruno S, Wands JR, (1994) Properties of hepatitis B virus pre-S1 deletion mutants. Virology 199: 292-300.
47. Iser DM, Avihingsanon A, Wisedopas N, Thompson AJ, Boyd A, et al. (2010) Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression. AIDS 25: 197-205.
48. Vermeulen M, Dickens C, Lelie N, Walker E, Coleman C, et al. (2012) Hepatitis B virus transmission by blood transfusion during 4 years of individual-donation nucleic acid testing in South Africa: estimated and observed window period risk. Transfusion 52: 880-892.
49. Lindh M, Andersson AS, Gusdal A, (1997) Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus-large-scale analysis using a new genotyping method. J Infect Dis 175: 1285-1293.
50. Takahashi K, Aoyama K, Ohno N, Iwata K, Akahane Y, et al. (1995) The precore/core promoter mutant (T1762A1764) of hepatitis B virus: clinical significance and an easy method for detection. J Gen Virol 76 (Pt 12):: 3159-3164.